| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematologic Neoplasms | 38 | 2024 | 329 | 11.440 |
Why?
|
| Germ-Line Mutation | 36 | 2024 | 329 | 9.500 |
Why?
|
| Genetic Predisposition to Disease | 45 | 2024 | 2270 | 6.770 |
Why?
|
| Leukemia, Myeloid, Acute | 41 | 2024 | 763 | 6.490 |
Why?
|
| Myelodysplastic Syndromes | 33 | 2024 | 346 | 6.400 |
Why?
|
| DNA Methylation | 42 | 2023 | 628 | 5.540 |
Why?
|
| Myeloproliferative Disorders | 12 | 2024 | 110 | 4.670 |
Why?
|
| Proto-Oncogene Proteins | 25 | 2022 | 645 | 3.530 |
Why?
|
| Cytosine | 18 | 2020 | 127 | 3.490 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 17 | 2022 | 55 | 3.170 |
Why?
|
| Hematopoiesis | 20 | 2023 | 163 | 2.900 |
Why?
|
| 5-Methylcytosine | 19 | 2022 | 112 | 2.850 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 12 | 2023 | 52 | 2.800 |
Why?
|
| Leukemia | 13 | 2023 | 320 | 2.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 25 | 2023 | 878 | 2.510 |
Why?
|
| Neoplasms | 18 | 2024 | 2897 | 2.420 |
Why?
|
| Epigenesis, Genetic | 22 | 2020 | 479 | 2.230 |
Why?
|
| Leukemia, Myeloid | 11 | 2023 | 249 | 2.210 |
Why?
|
| Germ Cells | 18 | 2024 | 126 | 2.090 |
Why?
|
| Neuroblastoma | 9 | 2022 | 374 | 2.040 |
Why?
|
| BRCA1 Protein | 4 | 2024 | 200 | 2.000 |
Why?
|
| Humans | 193 | 2024 | 86601 | 1.960 |
Why?
|
| DNA-Binding Proteins | 20 | 2020 | 1208 | 1.780 |
Why?
|
| Gene Expression Regulation, Neoplastic | 21 | 2022 | 1197 | 1.770 |
Why?
|
| Genetic Testing | 11 | 2022 | 535 | 1.650 |
Why?
|
| Mutation | 36 | 2024 | 3967 | 1.630 |
Why?
|
| Hematopoietic Stem Cells | 12 | 2023 | 292 | 1.610 |
Why?
|
| Dioxygenases | 16 | 2020 | 74 | 1.580 |
Why?
|
| Blood Donors | 3 | 2016 | 26 | 1.560 |
Why?
|
| Mixed Function Oxygenases | 4 | 2022 | 68 | 1.540 |
Why?
|
| Thrombocytopenia | 6 | 2021 | 183 | 1.510 |
Why?
|
| CpG Islands | 11 | 2020 | 151 | 1.430 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2020 | 456 | 1.420 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 171 | 1.420 |
Why?
|
| DEAD-box RNA Helicases | 5 | 2023 | 62 | 1.410 |
Why?
|
| Transplantation Conditioning | 21 | 2023 | 373 | 1.270 |
Why?
|
| Graft vs Host Disease | 10 | 2023 | 365 | 1.200 |
Why?
|
| Histones | 10 | 2023 | 311 | 1.200 |
Why?
|
| Azacitidine | 11 | 2020 | 137 | 1.190 |
Why?
|
| Anemia, Aplastic | 3 | 2023 | 30 | 1.170 |
Why?
|
| DNA Mutational Analysis | 9 | 2016 | 526 | 1.160 |
Why?
|
| Proto-Oncogene Proteins c-ets | 4 | 2022 | 25 | 1.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2010 | 173 | 1.100 |
Why?
|
| Bone Marrow | 5 | 2023 | 435 | 1.090 |
Why?
|
| Lymphoma | 6 | 2016 | 262 | 0.990 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2023 | 427 | 0.960 |
Why?
|
| Alleles | 5 | 2021 | 1127 | 0.960 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2020 | 120 | 0.960 |
Why?
|
| Nuclear Proteins | 8 | 2015 | 696 | 0.920 |
Why?
|
| Neoplasms, Second Primary | 5 | 2021 | 252 | 0.900 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 36 | 0.900 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 42 | 0.850 |
Why?
|
| Repressor Proteins | 5 | 2021 | 403 | 0.850 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2021 | 29 | 0.840 |
Why?
|
| Globins | 1 | 2021 | 31 | 0.840 |
Why?
|
| Neoplastic Stem Cells | 3 | 2016 | 143 | 0.810 |
Why?
|
| Female | 75 | 2023 | 44507 | 0.800 |
Why?
|
| Genome, Human | 6 | 2022 | 756 | 0.800 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 136 | 0.800 |
Why?
|
| Genetic Association Studies | 4 | 2021 | 294 | 0.780 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2020 | 5 | 0.780 |
Why?
|
| Transcription Factors | 10 | 2020 | 1565 | 0.780 |
Why?
|
| Cell Line, Tumor | 20 | 2022 | 2426 | 0.760 |
Why?
|
| Cell Differentiation | 10 | 2017 | 1458 | 0.730 |
Why?
|
| Myeloid Cells | 5 | 2017 | 98 | 0.720 |
Why?
|
| Adult | 50 | 2024 | 25640 | 0.710 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2019 | 9 | 0.710 |
Why?
|
| Animals | 47 | 2023 | 26581 | 0.700 |
Why?
|
| Male | 66 | 2023 | 40956 | 0.690 |
Why?
|
| Erythropoiesis | 3 | 2013 | 52 | 0.690 |
Why?
|
| DNA Modification Methylases | 4 | 2022 | 25 | 0.690 |
Why?
|
| Precision Medicine | 2 | 2021 | 395 | 0.680 |
Why?
|
| Antineoplastic Agents | 11 | 2022 | 2357 | 0.670 |
Why?
|
| Promoter Regions, Genetic | 13 | 2020 | 937 | 0.670 |
Why?
|
| Aged | 50 | 2021 | 18402 | 0.650 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2017 | 236 | 0.640 |
Why?
|
| Transplantation, Homologous | 23 | 2023 | 996 | 0.620 |
Why?
|
| BRCA2 Protein | 3 | 2024 | 158 | 0.620 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2016 | 50 | 0.620 |
Why?
|
| Genes, Tumor Suppressor | 6 | 2018 | 157 | 0.600 |
Why?
|
| Blood Platelet Disorders | 2 | 2021 | 9 | 0.600 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2017 | 148 | 0.600 |
Why?
|
| Disease Susceptibility | 4 | 2023 | 193 | 0.590 |
Why?
|
| Lymphoma, B-Cell | 2 | 2020 | 103 | 0.590 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 592 | 0.580 |
Why?
|
| X Chromosome Inactivation | 2 | 2015 | 28 | 0.560 |
Why?
|
| Cord Blood Stem Cell Transplantation | 5 | 2016 | 93 | 0.540 |
Why?
|
| Prognosis | 21 | 2022 | 3674 | 0.540 |
Why?
|
| Mice | 33 | 2021 | 11352 | 0.540 |
Why?
|
| Consensus | 2 | 2022 | 335 | 0.530 |
Why?
|
| Models, Biological | 5 | 2021 | 1749 | 0.520 |
Why?
|
| Chromosomes, Human, X | 1 | 2015 | 55 | 0.520 |
Why?
|
| Donor Selection | 1 | 2015 | 67 | 0.520 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 129 | 0.510 |
Why?
|
| RNA, Messenger | 9 | 2023 | 1981 | 0.510 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2014 | 279 | 0.510 |
Why?
|
| Cell Proliferation | 8 | 2018 | 1578 | 0.500 |
Why?
|
| Preleukemia | 1 | 2014 | 10 | 0.500 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 138 | 0.490 |
Why?
|
| Isocitrate Dehydrogenase | 5 | 2023 | 51 | 0.490 |
Why?
|
| Clonal Evolution | 1 | 2014 | 15 | 0.490 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2022 | 179 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2021 | 381 | 0.480 |
Why?
|
| Erythroid Cells | 1 | 2013 | 14 | 0.480 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2012 | 458 | 0.480 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2023 | 127 | 0.480 |
Why?
|
| DNA Repair Enzymes | 1 | 2014 | 52 | 0.480 |
Why?
|
| Epigenomics | 5 | 2019 | 100 | 0.470 |
Why?
|
| Genetic Variation | 5 | 2022 | 1351 | 0.470 |
Why?
|
| Stem Cell Transplantation | 4 | 2012 | 183 | 0.470 |
Why?
|
| Pedigree | 8 | 2020 | 966 | 0.460 |
Why?
|
| Dacarbazine | 1 | 2014 | 102 | 0.460 |
Why?
|
| Middle Aged | 49 | 2021 | 25017 | 0.460 |
Why?
|
| Antigens, CD34 | 10 | 2017 | 158 | 0.460 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 4 | 2021 | 21 | 0.460 |
Why?
|
| Sex Characteristics | 1 | 2015 | 319 | 0.460 |
Why?
|
| Haploinsufficiency | 2 | 2013 | 62 | 0.460 |
Why?
|
| Mitoxantrone | 4 | 2020 | 68 | 0.460 |
Why?
|
| Bone Marrow Cells | 3 | 2017 | 253 | 0.460 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 375 | 0.450 |
Why?
|
| Hypoxia | 4 | 2022 | 641 | 0.450 |
Why?
|
| Karyopherins | 1 | 2012 | 14 | 0.440 |
Why?
|
| Chromosome Deletion | 4 | 2011 | 229 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2018 | 2436 | 0.440 |
Why?
|
| GATA2 Transcription Factor | 4 | 2023 | 14 | 0.430 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 147 | 0.430 |
Why?
|
| Colon | 1 | 2015 | 496 | 0.430 |
Why?
|
| Histone Code | 1 | 2012 | 19 | 0.420 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2012 | 122 | 0.420 |
Why?
|
| Tissue Donors | 3 | 2012 | 463 | 0.400 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 556 | 0.400 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 2887 | 0.390 |
Why?
|
| Young Adult | 21 | 2021 | 5974 | 0.380 |
Why?
|
| Burkitt Lymphoma | 1 | 2010 | 31 | 0.380 |
Why?
|
| Sulfones | 2 | 2023 | 43 | 0.380 |
Why?
|
| Histone Deacetylase Inhibitors | 4 | 2017 | 85 | 0.370 |
Why?
|
| Hematology | 2 | 2020 | 29 | 0.370 |
Why?
|
| Mediastinal Neoplasms | 1 | 2010 | 46 | 0.370 |
Why?
|
| Antibodies, Neoplasm | 6 | 2010 | 84 | 0.370 |
Why?
|
| Acute Disease | 11 | 2022 | 826 | 0.360 |
Why?
|
| Biomarkers | 4 | 2021 | 1718 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 5 | 5 | 2021 | 109 | 0.360 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2021 | 71 | 0.350 |
Why?
|
| Cell Hypoxia | 3 | 2022 | 164 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2011 | 79 | 0.350 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2009 | 86 | 0.340 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 1169 | 0.340 |
Why?
|
| Base Sequence | 10 | 2019 | 2330 | 0.340 |
Why?
|
| Family | 4 | 2016 | 311 | 0.340 |
Why?
|
| Genetic Counseling | 3 | 2021 | 100 | 0.340 |
Why?
|
| Mastocytosis | 1 | 2008 | 13 | 0.330 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 232 | 0.330 |
Why?
|
| Telomerase | 3 | 2020 | 55 | 0.330 |
Why?
|
| Gene Expression Profiling | 9 | 2017 | 1384 | 0.330 |
Why?
|
| RNA Splicing | 2 | 2015 | 142 | 0.330 |
Why?
|
| Transcriptional Activation | 2 | 2020 | 280 | 0.330 |
Why?
|
| DNA | 2 | 2011 | 1294 | 0.320 |
Why?
|
| Aged, 80 and over | 19 | 2023 | 6501 | 0.320 |
Why?
|
| Aging | 3 | 2023 | 691 | 0.320 |
Why?
|
| HMGA2 Protein | 1 | 2007 | 14 | 0.310 |
Why?
|
| Cytarabine | 4 | 2020 | 218 | 0.310 |
Why?
|
| Cell Line | 5 | 2021 | 2468 | 0.310 |
Why?
|
| MicroRNAs | 2 | 2015 | 534 | 0.310 |
Why?
|
| Genomics | 8 | 2022 | 720 | 0.310 |
Why?
|
| Treatment Outcome | 18 | 2018 | 7988 | 0.300 |
Why?
|
| Translocation, Genetic | 4 | 2021 | 265 | 0.290 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2018 | 49 | 0.290 |
Why?
|
| Adolescent | 17 | 2021 | 8979 | 0.290 |
Why?
|
| Sulfonamides | 2 | 2021 | 300 | 0.290 |
Why?
|
| Risk Assessment | 3 | 2015 | 2261 | 0.280 |
Why?
|
| Penetrance | 2 | 2024 | 44 | 0.280 |
Why?
|
| Enzyme Inhibitors | 3 | 2013 | 639 | 0.280 |
Why?
|
| Chromosome Aberrations | 4 | 2021 | 387 | 0.280 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1464 | 0.280 |
Why?
|
| Telomere | 3 | 2021 | 108 | 0.270 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 4 | 2014 | 18 | 0.270 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1920 | 0.270 |
Why?
|
| Clone Cells | 2 | 2023 | 213 | 0.260 |
Why?
|
| Survival Analysis | 9 | 2021 | 1538 | 0.260 |
Why?
|
| Risk | 4 | 2021 | 674 | 0.260 |
Why?
|
| Pancytopenia | 2 | 2022 | 23 | 0.260 |
Why?
|
| Pyrimidines | 3 | 2021 | 370 | 0.260 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2010 | 107 | 0.260 |
Why?
|
| Gene Expression | 5 | 2023 | 1284 | 0.250 |
Why?
|
| Risk Factors | 9 | 2021 | 5416 | 0.250 |
Why?
|
| RNA Interference | 4 | 2018 | 369 | 0.250 |
Why?
|
| Clinical Decision-Making | 3 | 2022 | 257 | 0.250 |
Why?
|
| Phenotype | 10 | 2022 | 2377 | 0.250 |
Why?
|
| Mice, Transgenic | 9 | 2013 | 1540 | 0.250 |
Why?
|
| Biology | 2 | 2021 | 50 | 0.250 |
Why?
|
| Zinc Fingers | 2 | 2023 | 56 | 0.240 |
Why?
|
| Remission Induction | 10 | 2020 | 722 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 10 | 2020 | 3092 | 0.240 |
Why?
|
| Prevalence | 3 | 2023 | 1239 | 0.240 |
Why?
|
| RNA, Small Interfering | 4 | 2018 | 547 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 6 | 2010 | 1376 | 0.240 |
Why?
|
| Fibroblasts | 3 | 2022 | 729 | 0.240 |
Why?
|
| Disease Management | 3 | 2021 | 327 | 0.240 |
Why?
|
| Amides | 1 | 2023 | 60 | 0.240 |
Why?
|
| alpha Karyopherins | 1 | 2023 | 10 | 0.230 |
Why?
|
| Geriatric Assessment | 2 | 2015 | 166 | 0.230 |
Why?
|
| Haplotypes | 3 | 2016 | 642 | 0.230 |
Why?
|
| Hematologic Diseases | 2 | 2022 | 79 | 0.230 |
Why?
|
| Unrelated Donors | 3 | 2023 | 50 | 0.230 |
Why?
|
| Germinal Center | 2 | 2015 | 55 | 0.230 |
Why?
|
| Sequence Analysis, DNA | 5 | 2019 | 853 | 0.230 |
Why?
|
| Binding Sites | 4 | 2015 | 1098 | 0.230 |
Why?
|
| Cell Cycle Proteins | 4 | 2015 | 388 | 0.230 |
Why?
|
| Gene-Environment Interaction | 3 | 2024 | 103 | 0.220 |
Why?
|
| Australia | 1 | 2023 | 99 | 0.220 |
Why?
|
| Age of Onset | 2 | 2021 | 310 | 0.220 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 112 | 0.220 |
Why?
|
| Tetrasomy | 1 | 2022 | 2 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2018 | 860 | 0.220 |
Why?
|
| Histone Demethylases | 2 | 2023 | 30 | 0.220 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 532 | 0.220 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2022 | 23 | 0.220 |
Why?
|
| Adenine Nucleotides | 2 | 2013 | 63 | 0.220 |
Why?
|
| Arabinonucleosides | 2 | 2013 | 39 | 0.220 |
Why?
|
| Genes, p53 | 4 | 1997 | 109 | 0.220 |
Why?
|
| Cell Movement | 3 | 2022 | 758 | 0.210 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 165 | 0.210 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 299 | 0.210 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 52 | 0.210 |
Why?
|
| Genotype | 4 | 2021 | 1850 | 0.210 |
Why?
|
| Mastocytosis, Systemic | 2 | 2014 | 11 | 0.210 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2021 | 20 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 151 | 0.210 |
Why?
|
| HLA Antigens | 2 | 2016 | 232 | 0.210 |
Why?
|
| Quantitative Trait Loci | 3 | 2014 | 576 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2024 | 379 | 0.200 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 67 | 0.200 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2021 | 7 | 0.200 |
Why?
|
| Morpholines | 1 | 2021 | 65 | 0.200 |
Why?
|
| Megakaryocytes | 1 | 2021 | 36 | 0.200 |
Why?
|
| Telomere Shortening | 1 | 2021 | 23 | 0.200 |
Why?
|
| Molecular Sequence Data | 12 | 2015 | 3030 | 0.200 |
Why?
|
| Fetal Blood | 3 | 2017 | 90 | 0.200 |
Why?
|
| Janus Kinase 2 | 2 | 2019 | 57 | 0.190 |
Why?
|
| Bias | 1 | 2021 | 127 | 0.190 |
Why?
|
| Glioma | 1 | 2023 | 285 | 0.190 |
Why?
|
| Cysteine | 2 | 2011 | 135 | 0.190 |
Why?
|
| Mice, Knockout | 6 | 2015 | 1924 | 0.190 |
Why?
|
| Fetus | 1 | 2021 | 226 | 0.190 |
Why?
|
| Isoenzymes | 2 | 2012 | 271 | 0.190 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 307 | 0.190 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2020 | 17 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 1961 | 0.180 |
Why?
|
| Minority Groups | 1 | 2021 | 137 | 0.180 |
Why?
|
| Gene Frequency | 2 | 2019 | 677 | 0.180 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2020 | 62 | 0.180 |
Why?
|
| Face | 1 | 2020 | 114 | 0.180 |
Why?
|
| Mutation, Missense | 3 | 2018 | 276 | 0.180 |
Why?
|
| Alternative Splicing | 4 | 2015 | 201 | 0.180 |
Why?
|
| Indoles | 1 | 2021 | 318 | 0.180 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 104 | 0.180 |
Why?
|
| Chromosome Disorders | 1 | 2020 | 114 | 0.180 |
Why?
|
| Karyotype | 1 | 2019 | 33 | 0.180 |
Why?
|
| Molecular Sequence Annotation | 1 | 2019 | 67 | 0.170 |
Why?
|
| Proteins | 2 | 2008 | 777 | 0.170 |
Why?
|
| Carcinogenesis | 2 | 2023 | 195 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 132 | 0.170 |
Why?
|
| Endodeoxyribonucleases | 1 | 2018 | 11 | 0.170 |
Why?
|
| Superoxides | 1 | 2019 | 73 | 0.170 |
Why?
|
| Transcription, Genetic | 4 | 2020 | 1135 | 0.170 |
Why?
|
| Glutarates | 2 | 2023 | 8 | 0.170 |
Why?
|
| B-Lymphocytes | 2 | 2015 | 724 | 0.170 |
Why?
|
| Muscle Proteins | 1 | 1999 | 132 | 0.170 |
Why?
|
| Recurrence | 6 | 2023 | 1139 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 2 | 2017 | 217 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1313 | 0.170 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2016 | 90 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 1169 | 0.160 |
Why?
|
| Azepines | 2 | 2015 | 20 | 0.160 |
Why?
|
| Interleukin-6 | 3 | 2023 | 256 | 0.160 |
Why?
|
| Child | 8 | 2024 | 6926 | 0.160 |
Why?
|
| Protein Kinases | 1 | 1999 | 209 | 0.160 |
Why?
|
| Histocompatibility Testing | 3 | 2017 | 154 | 0.160 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2018 | 8 | 0.160 |
Why?
|
| Cytokines | 2 | 2019 | 776 | 0.160 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2018 | 40 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 41 | 0.160 |
Why?
|
| Mammary Neoplasms, Experimental | 5 | 1997 | 124 | 0.160 |
Why?
|
| Exome | 2 | 2015 | 127 | 0.150 |
Why?
|
| Zebrafish Proteins | 5 | 1997 | 144 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 1685 | 0.150 |
Why?
|
| Up-Regulation | 3 | 2015 | 712 | 0.150 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 2 | 2014 | 34 | 0.150 |
Why?
|
| Genes, Dominant | 1 | 2017 | 117 | 0.150 |
Why?
|
| Exons | 3 | 2015 | 450 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2011 | 930 | 0.150 |
Why?
|
| DNA Repair | 1 | 2019 | 356 | 0.150 |
Why?
|
| Alemtuzumab | 7 | 2011 | 83 | 0.150 |
Why?
|
| Health Planning Guidelines | 1 | 2016 | 24 | 0.150 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2011 | 623 | 0.140 |
Why?
|
| Gene Silencing | 3 | 2012 | 172 | 0.140 |
Why?
|
| Tretinoin | 2 | 2018 | 126 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 18 | 0.140 |
Why?
|
| Succinic Acid | 1 | 2015 | 6 | 0.140 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2015 | 266 | 0.140 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
| Haploidy | 1 | 2016 | 31 | 0.140 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2015 | 5 | 0.140 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 14 | 0.140 |
Why?
|
| Mice, Nude | 2 | 2021 | 790 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 425 | 0.140 |
Why?
|
| Fumarates | 1 | 2015 | 26 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2356 | 0.140 |
Why?
|
| Glycine | 1 | 2016 | 90 | 0.140 |
Why?
|
| Melphalan | 3 | 2011 | 97 | 0.140 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2818 | 0.140 |
Why?
|
| Lymphocyte Depletion | 2 | 2017 | 97 | 0.130 |
Why?
|
| Cytidine Deaminase | 1 | 2015 | 43 | 0.130 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 63 | 0.130 |
Why?
|
| Protein Isoforms | 3 | 2013 | 270 | 0.130 |
Why?
|
| Patients | 1 | 2016 | 100 | 0.130 |
Why?
|
| Mitochondria | 1 | 2019 | 535 | 0.130 |
Why?
|
| Models, Molecular | 4 | 2015 | 1286 | 0.130 |
Why?
|
| Survival Rate | 7 | 2014 | 1860 | 0.130 |
Why?
|
| Age Factors | 6 | 2018 | 1849 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 559 | 0.130 |
Why?
|
| WT1 Proteins | 1 | 2014 | 19 | 0.130 |
Why?
|
| Ascorbic Acid | 1 | 2015 | 37 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 105 | 0.130 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2013 | 154 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 101 | 0.130 |
Why?
|
| Ureter | 1 | 1996 | 92 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 101 | 0.130 |
Why?
|
| Vidarabine | 3 | 2010 | 141 | 0.130 |
Why?
|
| Triazoles | 1 | 2015 | 96 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 49 | 0.130 |
Why?
|
| Folic Acid | 1 | 2015 | 60 | 0.130 |
Why?
|
| Graft Survival | 3 | 2016 | 884 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2020 | 348 | 0.130 |
Why?
|
| Case-Control Studies | 3 | 2015 | 1804 | 0.130 |
Why?
|
| Immunophenotyping | 1 | 2015 | 211 | 0.120 |
Why?
|
| Microfluidics | 1 | 2015 | 51 | 0.120 |
Why?
|
| Apoptosis | 4 | 2013 | 1683 | 0.120 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 1204 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 2 | 2017 | 645 | 0.120 |
Why?
|
| Response Elements | 1 | 2014 | 63 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 408 | 0.120 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 265 | 0.120 |
Why?
|
| Disease Progression | 4 | 2016 | 1531 | 0.120 |
Why?
|
| Histocompatibility Antigens | 1 | 2013 | 35 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2022 | 8475 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 316 | 0.120 |
Why?
|
| Glucocorticoids | 1 | 2015 | 352 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 736 | 0.110 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 14 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2015 | 458 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 151 | 0.110 |
Why?
|
| Drug Administration Schedule | 4 | 2018 | 916 | 0.110 |
Why?
|
| Karyotyping | 2 | 2011 | 250 | 0.110 |
Why?
|
| Cerebellum | 2 | 2011 | 247 | 0.110 |
Why?
|
| Homeostasis | 2 | 2012 | 409 | 0.110 |
Why?
|
| Incidence | 5 | 2021 | 1576 | 0.110 |
Why?
|
| Chromatin | 1 | 2015 | 380 | 0.110 |
Why?
|
| Point Mutation | 2 | 2012 | 246 | 0.110 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2013 | 124 | 0.110 |
Why?
|
| Hemagglutinins, Viral | 1 | 1992 | 38 | 0.110 |
Why?
|
| Genes, BRCA1 | 2 | 2015 | 192 | 0.110 |
Why?
|
| Imatinib Mesylate | 2 | 2009 | 126 | 0.110 |
Why?
|
| Membrane Fusion | 1 | 1992 | 37 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2019 | 1106 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2014 | 255 | 0.100 |
Why?
|
| Viral Envelope Proteins | 1 | 1992 | 94 | 0.100 |
Why?
|
| Myelopoiesis | 1 | 2011 | 10 | 0.100 |
Why?
|
| Diet | 1 | 2015 | 443 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2012 | 125 | 0.100 |
Why?
|
| Comorbidity | 4 | 2018 | 943 | 0.100 |
Why?
|
| Dinucleoside Phosphates | 1 | 2011 | 9 | 0.100 |
Why?
|
| Benzamides | 2 | 2009 | 229 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.100 |
Why?
|
| Genome-Wide Association Study | 3 | 2017 | 1620 | 0.100 |
Why?
|
| Graft vs Tumor Effect | 1 | 2010 | 25 | 0.100 |
Why?
|
| Biotin | 1 | 2010 | 44 | 0.100 |
Why?
|
| Carbazoles | 1 | 2011 | 51 | 0.100 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 19 | 0.100 |
Why?
|
| Busulfan | 1 | 2010 | 39 | 0.100 |
Why?
|
| Catalytic Domain | 1 | 2011 | 156 | 0.100 |
Why?
|
| DNA Mismatch Repair | 1 | 2010 | 52 | 0.100 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 41 | 0.100 |
Why?
|
| Piperazines | 2 | 2009 | 272 | 0.090 |
Why?
|
| Staining and Labeling | 1 | 2010 | 165 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2011 | 233 | 0.090 |
Why?
|
| Family Health | 1 | 2010 | 162 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2011 | 347 | 0.090 |
Why?
|
| Microfilament Proteins | 3 | 2001 | 208 | 0.090 |
Why?
|
| Kidney | 1 | 1996 | 1241 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1065 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 196 | 0.090 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2008 | 126 | 0.090 |
Why?
|
| Neutropenia | 1 | 2010 | 215 | 0.090 |
Why?
|
| Transplantation Chimera | 1 | 2009 | 80 | 0.090 |
Why?
|
| Tissue Distribution | 3 | 2000 | 290 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2014 | 2767 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2009 | 43 | 0.090 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 485 | 0.090 |
Why?
|
| Transfer RNA Aminoacylation | 1 | 2009 | 18 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 819 | 0.090 |
Why?
|
| Proteasome Inhibitors | 1 | 2009 | 51 | 0.090 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2015 | 416 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2009 | 55 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 72 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2018 | 1937 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 275 | 0.080 |
Why?
|
| Outpatients | 1 | 2009 | 94 | 0.080 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2008 | 5 | 0.080 |
Why?
|
| Heart | 1 | 2012 | 539 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 857 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2023 | 4210 | 0.080 |
Why?
|
| Kruppel-Like Factor 6 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Pyrazines | 1 | 2009 | 92 | 0.080 |
Why?
|
| Infant | 3 | 2021 | 3045 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 87 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2021 | 3611 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2008 | 56 | 0.080 |
Why?
|
| Blood Component Removal | 1 | 2008 | 24 | 0.080 |
Why?
|
| Quinoxalines | 1 | 2008 | 50 | 0.080 |
Why?
|
| Hippocampus | 1 | 2011 | 442 | 0.080 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2008 | 93 | 0.080 |
Why?
|
| Sequence Deletion | 1 | 2008 | 205 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2008 | 190 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 295 | 0.080 |
Why?
|
| Genome | 1 | 2010 | 372 | 0.080 |
Why?
|
| RNA, Transfer | 1 | 2009 | 151 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 3 | 2014 | 270 | 0.080 |
Why?
|
| Amino Acid Sequence | 4 | 2015 | 2062 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2008 | 314 | 0.080 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 162 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 1041 | 0.080 |
Why?
|
| Mycoses | 1 | 2007 | 46 | 0.080 |
Why?
|
| Transplantation, Haploidentical | 2 | 2017 | 27 | 0.080 |
Why?
|
| Karnofsky Performance Status | 1 | 2006 | 40 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 273 | 0.070 |
Why?
|
| Leukocytes | 1 | 2007 | 202 | 0.070 |
Why?
|
| Radiotherapy | 1 | 2008 | 328 | 0.070 |
Why?
|
| Ganciclovir | 1 | 2006 | 49 | 0.070 |
Why?
|
| Flow Cytometry | 2 | 2021 | 679 | 0.070 |
Why?
|
| Valine | 1 | 2006 | 69 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2016 | 220 | 0.070 |
Why?
|
| Acyclovir | 1 | 2006 | 107 | 0.070 |
Why?
|
| Introns | 2 | 2013 | 289 | 0.070 |
Why?
|
| Lung | 1 | 2012 | 1170 | 0.070 |
Why?
|
| Caenorhabditis elegans | 1 | 2007 | 223 | 0.070 |
Why?
|
| Registries | 2 | 2021 | 702 | 0.070 |
Why?
|
| Cloning, Molecular | 2 | 2012 | 646 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 144 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1034 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 286 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2378 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2021 | 782 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 728 | 0.060 |
Why?
|
| DNA Primers | 3 | 2002 | 543 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 744 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2023 | 589 | 0.060 |
Why?
|
| Conserved Sequence | 2 | 2015 | 210 | 0.060 |
Why?
|
| Transcriptome | 2 | 2020 | 580 | 0.060 |
Why?
|
| Microarray Analysis | 2 | 2015 | 96 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2009 | 629 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 2 | 2000 | 29 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2013 | 689 | 0.060 |
Why?
|
| Morbidity | 1 | 2023 | 148 | 0.060 |
Why?
|
| Methylation | 2 | 2015 | 251 | 0.060 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2022 | 30 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2021 | 692 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2013 | 295 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 103 | 0.050 |
Why?
|
| Porosity | 2 | 2015 | 60 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2021 | 27 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2021 | 17 | 0.050 |
Why?
|
| Gene Regulatory Networks | 2 | 2017 | 296 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2013 | 927 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2006 | 510 | 0.050 |
Why?
|
| Syndrome | 1 | 2022 | 446 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2015 | 498 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 2705 | 0.050 |
Why?
|
| Heterozygote | 1 | 2022 | 365 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 189 | 0.050 |
Why?
|
| Naphthyridines | 1 | 2021 | 53 | 0.050 |
Why?
|
| Physical Chromosome Mapping | 1 | 2001 | 27 | 0.050 |
Why?
|
| California | 1 | 2021 | 138 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2021 | 303 | 0.050 |
Why?
|
| Muscle Hypotonia | 1 | 2021 | 45 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 879 | 0.050 |
Why?
|
| Microcephaly | 1 | 2021 | 75 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3636 | 0.050 |
Why?
|
| Illinois | 2 | 2012 | 462 | 0.050 |
Why?
|
| Animals, Newborn | 2 | 2012 | 510 | 0.050 |
Why?
|
| Chromosome Breakage | 1 | 2020 | 17 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2011 | 273 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 751 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2021 | 182 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 86 | 0.050 |
Why?
|
| Connectin | 1 | 1999 | 5 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 2001 | 673 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2015 | 1014 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2021 | 195 | 0.040 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2021 | 245 | 0.040 |
Why?
|
| Molecular Weight | 1 | 1999 | 332 | 0.040 |
Why?
|
| Quality of Life | 1 | 2007 | 1583 | 0.040 |
Why?
|
| Mammary Tumor Virus, Mouse | 2 | 1996 | 63 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1996 | 135 | 0.040 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 22 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 1999 | 393 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2018 | 46 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 2232 | 0.040 |
Why?
|
| Motor Activity | 1 | 2021 | 327 | 0.040 |
Why?
|
| Aneuploidy | 2 | 1996 | 55 | 0.040 |
Why?
|
| Lactobacillus | 1 | 2018 | 21 | 0.040 |
Why?
|
| Paraproteins | 1 | 2018 | 4 | 0.040 |
Why?
|
| Wnt Proteins | 5 | 1997 | 123 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2018 | 76 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 158 | 0.040 |
Why?
|
| Cyclin D2 | 1 | 2018 | 19 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2011 | 369 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 1999 | 223 | 0.040 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2018 | 5 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
| Germ-Free Life | 1 | 2018 | 69 | 0.040 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2018 | 33 | 0.040 |
Why?
|
| Permeability | 1 | 2018 | 137 | 0.040 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 977 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 373 | 0.040 |
Why?
|
| United States | 2 | 2021 | 6665 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2009 | 429 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2019 | 177 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 81 | 0.040 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 19 | 0.040 |
Why?
|
| Plasma Cells | 1 | 2018 | 80 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2017 | 24 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2017 | 79 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 277 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 357 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2007 | 2207 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 1673 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 391 | 0.040 |
Why?
|
| Transfection | 2 | 2010 | 896 | 0.040 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 41 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 182 | 0.040 |
Why?
|
| Blood Urea Nitrogen | 1 | 1996 | 34 | 0.040 |
Why?
|
| Texas | 1 | 2016 | 101 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2016 | 28 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2015 | 14 | 0.030 |
Why?
|
| Chimerism | 1 | 2016 | 37 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 71 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 447 | 0.030 |
Why?
|
| Bone Marrow Diseases | 1 | 2015 | 40 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 77 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 1996 | 141 | 0.030 |
Why?
|
| Mesoderm | 1 | 1996 | 108 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 307 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2011 | 329 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 2501 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 488 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 79 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1056 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 309 | 0.030 |
Why?
|
| Organ Size | 1 | 1996 | 364 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 24 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 149 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 106 | 0.030 |
Why?
|
| Proto-Oncogenes | 2 | 2010 | 61 | 0.030 |
Why?
|
| Cell Division | 2 | 2011 | 696 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 160 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 74 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 122 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 307 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2015 | 268 | 0.030 |
Why?
|
| Cocarcinogenesis | 1 | 1994 | 12 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 557 | 0.030 |
Why?
|
| Cadherins | 1 | 2015 | 151 | 0.030 |
Why?
|
| Genetics, Medical | 1 | 2014 | 52 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 226 | 0.030 |
Why?
|
| Chromosome Mapping | 2 | 2011 | 1074 | 0.030 |
Why?
|
| Smad1 Protein | 1 | 2013 | 3 | 0.030 |
Why?
|
| Glycosyltransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2013 | 34 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 229 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2015 | 134 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2016 | 326 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 117 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 528 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 32 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2013 | 83 | 0.030 |
Why?
|
| beta Catenin | 1 | 2015 | 251 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 1047 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 59 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 64 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 552 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 159 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 94 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 797 | 0.030 |
Why?
|
| Epistasis, Genetic | 1 | 2013 | 86 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 920 | 0.030 |
Why?
|
| Wnt1 Protein | 3 | 1997 | 24 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 97 | 0.030 |
Why?
|
| Bromelains | 1 | 1992 | 1 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2013 | 260 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 1992 | 49 | 0.030 |
Why?
|
| Trypsin | 1 | 1992 | 95 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2012 | 25 | 0.030 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1992 | 70 | 0.030 |
Why?
|
| Sulfites | 1 | 2012 | 26 | 0.030 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2011 | 16 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2011 | 39 | 0.030 |
Why?
|
| Erythrocytes | 1 | 2013 | 255 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 16 | 0.030 |
Why?
|
| Quinazolines | 1 | 2013 | 220 | 0.030 |
Why?
|
| Rett Syndrome | 1 | 2011 | 19 | 0.030 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 30 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2011 | 40 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 124 | 0.030 |
Why?
|
| Granulocytes | 1 | 2011 | 37 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 134 | 0.030 |
Why?
|
| Lentivirus | 1 | 2011 | 36 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 366 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 279 | 0.030 |
Why?
|
| Core Binding Factors | 1 | 2011 | 12 | 0.030 |
Why?
|
| Sheep | 1 | 2011 | 239 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 77 | 0.020 |
Why?
|
| Furans | 1 | 2011 | 16 | 0.020 |
Why?
|
| CCCTC-Binding Factor | 1 | 2011 | 18 | 0.020 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2010 | 6 | 0.020 |
Why?
|
| X Chromosome | 1 | 2011 | 152 | 0.020 |
Why?
|
| Bacteriophage T4 | 1 | 2010 | 8 | 0.020 |
Why?
|
| Hydroxylation | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cricetinae | 1 | 1992 | 560 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 26 | 0.020 |
Why?
|
| GATA1 Transcription Factor | 1 | 2010 | 18 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2011 | 72 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2011 | 258 | 0.020 |
Why?
|
| Glucosyltransferases | 1 | 2010 | 25 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 96 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 182 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 68 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1996 | 509 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 493 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1456 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 121 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 94 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 372 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2010 | 21 | 0.020 |
Why?
|
| Valproic Acid | 1 | 2010 | 24 | 0.020 |
Why?
|
| Stem Cells | 1 | 2013 | 351 | 0.020 |
Why?
|
| Acetylation | 1 | 2010 | 121 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 263 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 224 | 0.020 |
Why?
|
| Cell Shape | 1 | 2010 | 51 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 133 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 384 | 0.020 |
Why?
|
| Monocytes | 1 | 2011 | 214 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 439 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 135 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 912 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 261 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 468 | 0.020 |
Why?
|
| Bortezomib | 1 | 2009 | 76 | 0.020 |
Why?
|
| Protein Conformation | 1 | 1992 | 881 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 504 | 0.020 |
Why?
|
| Myeloablative Agonists | 1 | 2008 | 34 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 839 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 615 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2001 | 302 | 0.020 |
Why?
|
| Half-Life | 1 | 2008 | 96 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2008 | 102 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3241 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 373 | 0.020 |
Why?
|
| Protein Transport | 1 | 2009 | 411 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 287 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1801 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 378 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 286 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2008 | 330 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2007 | 117 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2008 | 238 | 0.020 |
Why?
|
| Hyperplasia | 2 | 1997 | 148 | 0.020 |
Why?
|
| Crosses, Genetic | 2 | 1997 | 171 | 0.020 |
Why?
|
| Mammary Glands, Animal | 2 | 1997 | 78 | 0.020 |
Why?
|
| Length of Stay | 1 | 2008 | 700 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 3990 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1990 | 0.010 |
Why?
|
| Chromosomes, Artificial, Human | 1 | 2001 | 2 | 0.010 |
Why?
|
| Apc8 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 2001 | 2 | 0.010 |
Why?
|
| Nuclear Localization Signals | 1 | 2000 | 10 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 130 | 0.010 |
Why?
|
| Time Factors | 1 | 2009 | 5209 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 2000 | 64 | 0.010 |
Why?
|
| Tandem Repeat Sequences | 1 | 2000 | 26 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 116 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 2000 | 117 | 0.010 |
Why?
|
| Insect Proteins | 1 | 2000 | 88 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 351 | 0.010 |
Why?
|
| Mitosis | 1 | 1997 | 153 | 0.010 |
Why?
|
| RNA Polymerase III | 1 | 1996 | 7 | 0.010 |
Why?
|
| Mitogens | 1 | 1996 | 64 | 0.010 |
Why?
|
| Drosophila | 1 | 2000 | 498 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1996 | 72 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 203 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1996 | 269 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 1994 | 80 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1994 | 153 | 0.010 |
Why?
|